New collaboration with Dr David Durantel’s team

Following the positive proof-of-concept data from 203 study of Vonafexor in combination with pegylated-Interferon (peg-IFN) in viremic patients with chronic hepatitis B (CHB), a new collaboration was initiated with the team of David Durantel at the International Center for Research in Infectiology (CIRI – INSERM U1111, https://ciri.ens-lyon.fr/teams/HepVir).

Read more »

Published on 30/09/2021

Annual National Liver Conference – San Antonio

October 1st, 2021
San Antonio, USA

ENYO Pharma will sponsor the 16th Annual National Liver Conference.
https://www.liverconference.com/

Read more »

Published on 17/09/2021

Paris NASH Meeting

September 9-10, 2021
Paris

ENYO Pharma team will be present at the 7th edition of this event organized by Arun Sanyal and Lawrence Serfaty.
https://www.paris-nash.org/

Read more »

Published on 03/09/2021

2021 International HBV Meeting

26-30 September 2021
Toronto, Hybrid event

ENYO Pharma team will be present at this event organized by The Hepatitis B Foundation.
https://www.hbvmeeting.org/r

Read more »

Published on 03/09/2021

ENYO Pharma Announces 16 Weeks Vonafexor (EYP001) Top-Line Interim Results from Two on-going Phase 2a Studies in Chronic Hepatitis B Patients

Lyon, France. July 30, 2021 – ENYO Pharma (ENYO), a private clinical stage biotechnology company developing innovative drug candidates, today announced positive proof of concept data from Study EYP001-203 of Vonafexor in combination with pegylated-Interferon (peg-IFN) in viremic patients with chronic hepatitis B (CHB).

Read more »

Published on 30/07/2021